Drug Profile
Research programme: cancer therapeutics - Episynesis
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Episynesis
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Multiple myeloma
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Cancer in United Kingdom
- 28 Sep 2020 No recent reports of development identified for research development in Multiple-myeloma in United Kingdom
- 04 Aug 2016 Early research in Cancer in United Kingdom (unspecified route)